FDA Extends Review Of Takeda's NDA For FDC Of Alogliptin, ACTOS
Published: 22-Jul-2009
ACTOS, used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes
FDA has extended the review of Takeda's New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS (pioglitazone HCl).
Reportedly, the NDA for the FDC of alogliptin and ACTOS was submitted in September 2008, following the NDA submission of alogliptin monotherapy in December 2007.
ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes, said the company.
Takeda market oral diabetes, insomnia, rheumatology and gastroenterology treatments. The company has a product pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions.
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
White Papers
Browse A-Z
GRACO's New FDA Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New Hydra-Clean
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New 1590 & 3150 Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
Customer Testimonial – Astra Zeneca
From the control room to the downstream processing area and with an eye on utilities servi ...
Hygienic Processing
From the control room to the downstream processing area and with an eye on utilities servi ...
